Suven Pharmaceuticals ‘s Q2 Report: Revenue Rises by 11.54% YoY

The comprehensive analytics outlining the performance and outlook of Suven Pharmaceuticals Limited‘s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at Suven Pharmaceuticals Limited’s financial performance for the Q2(Sep 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 11.54 %. However, it did see a marginal increase of 11.72 % from the previous quarter. Expenses ticked up slightly by 1.95 % quarter-on-quarter, aligning with the annual rise of 15.48 %. Operating profit, while up 6.19 % compared to last year, faced a quarter-on-quarter increase of 30.14 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -2.03 %, but an expansion of 5.72 % sequentially. Other income fell by -22.23 % compared to the last quarter, despite an annual decline of -28.84 %. Interest expenses surged remarkably by 4.37 % from the previous quarter, yet the year-over-year increase remains at a moderate 234 %. Depreciation costs climbed by 26.57 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 42.64 %. Profit before tax declined annually by -5.6 % but saw an increase from the preceding quarter by 19.76 %.
Tax expenses as a percentage of profits decreased slightly by -6.91 % compared to last year, with a more notable quarter-on-quarter decrease of -9.26 %. Net profit rose by 3.04 % year-on-year but experienced a 34.92 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 2.56 % but a quarterly rise of 34.31 %. In summary, Suven Pharmaceuticals Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing Suven Pharmaceuticals Limited’s 2024-25(Q2) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 11.54 % year-on-year growth, however, there was a minor increase of 11.72 % from the previous quarter. Expenses rose by 15.48 % compared to the previous year, with a 1.95 % increase quarter-on-quarter. Operating Profit surged by 6.19 % annually, and saw a 30.14 % increase from the last quarter.
Net Profit showed yearly increase of 3.04 %, and experienced a 34.92 % increase from the previous quarter. Earnings Per Share (EPS) rose by 2.56 % annually, however rose by 34.31 % compared to the last quarter. In essence, while Suven Pharmaceuticals Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.